Type 2 Diabetes – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Type 2 Diabetes – Pipeline Review, H2 2017’, provides an overview of the Type 2 Diabetes pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Type 2 Diabetes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes

The report reviews pipeline therapeutics for Type 2 Diabetes by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Type 2 Diabetes therapeutics and enlists all their major and minor projects

The report assesses Type 2 Diabetes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Type 2 Diabetes

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4P Therapeutics LLC

Addex Therapeutics Ltd

Adocia SAS

Aegis Therapeutics LLC

AFFiRiS AG

Allergan Plc

Amarantus Bioscience Holdings Inc

Amgen Inc

AntriaBio Inc

Aphios Corp

Araim Pharmaceuticals Inc

Arecor Ltd

Arena Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

AusBio Ltd

Avadel Pharmaceuticals Plc

Bayer AG

Betagenon AB

Betta Pharmaceuticals Co Ltd

Biocon Ltd

BioLingus AG

BioRestorative Therapies Inc

Biozeus

Biscayne Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Boston Therapeutics Inc

Braasch Biotech LLC

Bristol-Myers Squibb Co

C4X Discovery Holdings PLC

Cadila Healthcare Ltd

Cadila Pharmaceuticals Ltd

Caelus Health

Cardax Inc

Carmot Therapeutics Inc

Celon Pharma SA

Center Laboratories Inc

Chipscreen Biosciences Ltd

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

CohBar Inc

Concenter BioPharma Silkim Ltd

Connexios Life Sciences Pvt Ltd

ConSynance Therapeutics Inc

CSL Ltd

CureDM Inc

CymaBay Therapeutics Inc

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Dance Biopharm Inc

Delpor Inc

Diabetology (Products) Ltd

DiaMedica Therapeutics Inc

Diamyd Medical AB

Diasome Pharmaceuticals Inc

DiscoveryBiomed Inc

DNJ Pharma Inc

Dong-A Socio Holdings Co Ltd

Elcelyx Therapeutics Inc

Eli Lilly and Co

Energenesis Biomedical Co Ltd

Enteris BioPharma Inc

Enzene Biosciences Ltd

Enzo Biochem Inc

Epichem Pty Ltd

Eternygen GmbH

Evotec AG

F. Hoffmann-La Roche Ltd

Genexine Inc

Genfit SA

Genmedica Therapeutics SL

Genovate Biotechnology Co LTD

Geropharm LLC

Gilead Sciences Inc

GlaxoSmithKline Plc

Glucox Biotech AB

Hanmi Pharmaceuticals Co Ltd

Heptares Therapeutics Ltd

HitGen LTD

Hyundai Pharmaceutical Co Ltd

Immuron Ltd

Inflazome Ltd

Innovative Targeting Solutions Inc

Inspyr Therapeutics Inc

InStar Technologies AS

Intarcia Therapeutics Inc

Intas Pharmaceuticals Ltd

Integral Molecular Inc

Intercept Pharmaceuticals Inc

Intrexon Corp

Ionis Pharmaceuticals Inc

Islet Sciences Inc

Japan Tobacco Inc

Jeil Pharmaceutical Co Ltd

JHL Biotech Inc

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Kadimastem Ltd

Kadmon Corp LLC

Kissei Pharmaceutical Co Ltd

Kowa Co Ltd

Lead Discovery Center GmbH

Leading BioSciences Inc

Lexicon Pharmaceuticals Inc

LG Chem Ltd

Ligand Pharmaceuticals Inc

LipimetiX Development Inc

Longevity Biotech Inc

Luye Pharma Group Ltd

Magnus Life Ltd

MannKind Corp

Medesis Pharma SA

Medestea Research & Production SpA

MedImmune LLC

Medlab Clinical Ltd

Melior Discovery Inc

Mellitech SAS

Merck & Co Inc

Mesoblast Ltd

Metabolic Solutions Development Company LLC

Metabolys SAS

Metacrine Inc

Mitsubishi Chemical Holdings Corp

Mitsubishi Tanabe Pharma Corp

Naia Ltd

Neurimmune Holding AG

Neurocrine Biosciences Inc

NGM Biopharmaceuticals Inc

Nordic Bioscience A/S

Novapeutics LLC

Novartis AG

NovaTarg Therapeutics Inc

Novo Nordisk AS

Omeros Corp

OPKO Biologics Ltd

OPKO Health Inc

Oramed Pharmaceuticals Inc

Paras Biopharmaceuticals Finland Oy

Peptron Inc

Pfizer Inc

PharmaCyte Biotech Inc

PharmaIN Corp

Pila Pharma AB

Poxel SA

Prometheon Pharma LLC

ProMetic Life Sciences Inc

Prothena Corp Plc

Purzer Pharmaceutical Co Ltd

Reata Pharmaceuticals Inc

ReCyte Therapeutics Inc

reMYND NV

Renova Therapeutics Inc

Reset Therapeutics Inc

Saniona AB

Sanofi

Sanwa Kagaku Kenkyusho Co Ltd

SATT Conectus Alsace SAS

SBI Pharmaceuticals Co Ltd

Seres Therapeutics Inc

Serodus ASA

Serometrix LLC

Sevion Therapeutics Inc

Shenzhen HighTide Biopharmaceutical Ltd

Shionogi & Co Ltd

Sirona Biochem Corp

SJT Molecular Research SL

SK Chemicals Co Ltd

Sprint Bioscience AB

Sumitomo Dainippon Pharma Co Ltd

Suzuken Co Ltd

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Co Ltd

Tasly Pharmaceutical Group Co Ltd

Teijin Pharma Ltd

The Medicines Company

Theracos Inc

Thermalin Diabetes LLC

Tiziana Life Sciences Plc

Toray Industries Inc

Torrent Pharmaceuticals Ltd

Transgene Biotek Ltd

TTY Biopharm Company Ltd

Twoxar Inc

Uni-Bio Science Group Ltd

ViaCyte Inc

Vichem Chemie Research Ltd

Vicore Pharma AB

Viking Therapeutics Inc

Vivus Inc

vTv Therapeutics Inc

Vybion Inc

XBiotech Inc

XL-protein GmbH

XOMA Corp

XuanZhu Pharma Co Ltd

Yabao Pharmaceutical Group Co Ltd

Yuhan Corp

Yungjin Pharm Co Ltd

Zafgen Inc

Zealand Pharma AS

Table of Contents

Table of Contents

Table of Contents 2

Introduction 10

Type 2 Diabetes - Overview 11

Type 2 Diabetes - Therapeutics Development 12

Type 2 Diabetes - Therapeutics Assessment 66

Type 2 Diabetes - Companies Involved in Therapeutics Development 88

Type 2 Diabetes - Drug Profiles 180

Type 2 Diabetes - Dormant Projects 1018

Type 2 Diabetes - Discontinued Products 1050

Type 2 Diabetes - Product Development Milestones 1060

Appendix 1070

List of Tables

List of Tables

Number of Products under Development for Type 2 Diabetes, H2 2017 67

Number of Products under Development by Companies, H2 2017 69

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 70

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 71

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 72

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 73

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 74

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 75

Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 76

Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017 77

Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017 78

Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017 79

Number of Products under Development by Companies, H2 2017 (Contd..11), H2 2017 80

Number of Products under Development by Companies, H2 2017 (Contd..12), H2 2017 81

Number of Products under Development by Companies, H2 2017 (Contd..13), H2 2017 82

Number of Products under Development by Companies, H2 2017 (Contd..14), H2 2017 83

Number of Products under Development by Universities/Institutes, H2 2017 84

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 86

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 87

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017 88

Products under Development by Companies, H2 2017 89

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 90

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 91

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 92

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 93

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 94

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 95

Products under Development by Companies, H2 2017 (Contd..7), H2 2017 96

Products under Development by Companies, H2 2017 (Contd..8), H2 2017 97

Products under Development by Companies, H2 2017 (Contd..9), H2 2017 98

Products under Development by Companies, H2 2017 (Contd..10), H2 2017 99

Products under Development by Companies, H2 2017 (Contd..11), H2 2017 100

Products under Development by Companies, H2 2017 (Contd..12), H2 2017 101

Products under Development by Companies, H2 2017 (Contd..13), H2 2017 102

Products under Development by Companies, H2 2017 (Contd..14), H2 2017 103

Products under Development by Companies, H2 2017 (Contd..15), H2 2017 104

Products under Development by Companies, H2 2017 (Contd..16), H2 2017 105

Products under Development by Companies, H2 2017 (Contd..17), H2 2017 106

Products under Development by Companies, H2 2017 (Contd..18), H2 2017 107

Products under Development by Companies, H2 2017 (Contd..19), H2 2017 108

Products under Development by Companies, H2 2017 (Contd..20), H2 2017 109

Products under Development by Companies, H2 2017 (Contd..21), H2 2017 110

Products under Development by Companies, H2 2017 (Contd..22), H2 2017 111

Products under Development by Companies, H2 2017 (Contd..23), H2 2017 112

Products under Development by Companies, H2 2017 (Contd..24), H2 2017 113

Products under Development by Companies, H2 2017 (Contd..25), H2 2017 114

Products under Development by Companies, H2 2017 (Contd..26), H2 2017 115

Products under Development by Universities/Institutes, H2 2017 116

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 117

Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 118

Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017 119

Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017 120

Number of Products by Stage and Target, H2 2017 122

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 123

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 124

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 125

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 126

Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 127

Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017 128

Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017 129

Number of Products by Stage and Mechanism of Action, H2 2017 131

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 132

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 133

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 134

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 135

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 136

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017 137

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017 138

Number of Products by Stage and Route of Administration, H2 2017 140

Number of Products by Stage and Molecule Type, H2 2017 142

Type 2 Diabetes – Pipeline by 4P Therapeutics LLC, H2 2017 143

Type 2 Diabetes – Pipeline by Addex Therapeutics Ltd, H2 2017 143

Type 2 Diabetes – Pipeline by Adocia SAS, H2 2017 144

Type 2 Diabetes – Pipeline by Aegis Therapeutics LLC, H2 2017 144

Type 2 Diabetes – Pipeline by AFFiRiS AG, H2 2017 145

Type 2 Diabetes – Pipeline by Allergan Plc, H2 2017 145

Type 2 Diabetes – Pipeline by Amarantus Bioscience Holdings Inc, H2 2017 145

Type 2 Diabetes – Pipeline by Amgen Inc, H2 2017 146

Type 2 Diabetes – Pipeline by AntriaBio Inc, H2 2017 147

Type 2 Diabetes – Pipeline by Aphios Corp, H2 2017 147

Type 2 Diabetes – Pipeline by Araim Pharmaceuticals Inc, H2 2017 147

Type 2 Diabetes – Pipeline by Arecor Ltd, H2 2017 148

Type 2 Diabetes – Pipeline by Arena Pharmaceuticals Inc, H2 2017 148

Type 2 Diabetes – Pipeline by Astellas Pharma Inc, H2 2017 149

Type 2 Diabetes – Pipeline by AstraZeneca Plc, H2 2017 149

Type 2 Diabetes – Pipeline by AusBio Ltd, H2 2017 150

Type 2 Diabetes – Pipeline by Avadel Pharmaceuticals Plc, H2 2017 150

Type 2 Diabetes – Pipeline by Bayer AG, H2 2017 151

Type 2 Diabetes – Pipeline by Betagenon AB, H2 2017 151

Type 2 Diabetes – Pipeline by Betta Pharmaceuticals Co Ltd, H2 2017 152

Type 2 Diabetes – Pipeline by Biocon Ltd, H2 2017 152

Type 2 Diabetes – Pipeline by BioLingus AG, H2 2017 153

Type 2 Diabetes – Pipeline by BioRestorative Therapies Inc, H2 2017 153

Type 2 Diabetes – Pipeline by Biozeus, H2 2017 153

Type 2 Diabetes – Pipeline by Biscayne Pharmaceuticals Inc, H2 2017 154

Type 2 Diabetes – Pipeline by Boehringer Ingelheim GmbH, H2 2017 154

Type 2 Diabetes – Pipeline by Boston Therapeutics Inc, H2 2017 155

Type 2 Diabetes – Pipeline by Braasch Biotech LLC, H2 2017 155

Type 2 Diabetes – Pipeline by Bristol-Myers Squibb Co, H2 2017 156

Type 2 Diabetes – Pipeline by C4X Discovery Holdings PLC, H2 2017 156

Type 2 Diabetes – Pipeline by Cadila Healthcare Ltd, H2 2017 157

Type 2 Diabetes – Pipeline by Cadila Pharmaceuticals Ltd, H2 2017 157

Type 2 Diabetes – Pipeline by Caelus Health, H2 2017 157

Type 2 Diabetes – Pipeline by Cardax Inc, H2 2017 158

Type 2 Diabetes – Pipeline by Carmot Therapeutics Inc, H2 2017 158

Type 2 Diabetes – Pipeline by Celon Pharma SA, H2 2017 159

Type 2 Diabetes – Pipeline by Center Laboratories Inc, H2 2017 159

Type 2 Diabetes – Pipeline by Chipscreen Biosciences Ltd, H2 2017 160

Type 2 Diabetes – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 160

Type 2 Diabetes – Pipeline by CJ HealthCare Corp, H2 2017 161

Type 2 Diabetes – Pipeline by CohBar Inc, H2 2017 161

Type 2 Diabetes – Pipeline by Concenter BioPharma Silkim Ltd, H2 2017 162

Type 2 Diabetes – Pipeline by Connexios Life Sciences Pvt Ltd, H2 2017 162

Type 2 Diabetes – Pipeline by ConSynance Therapeutics Inc, H2 2017 162

Type 2 Diabetes – Pipeline by CSL Ltd, H2 2017 163

Type 2 Diabetes – Pipeline by CureDM Inc, H2 2017 163

Type 2 Diabetes – Pipeline by CymaBay Therapeutics Inc, H2 2017 164

Type 2 Diabetes – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017 164

Type 2 Diabetes – Pipeline by Daiichi Sankyo Co Ltd, H2 2017 165

Type 2 Diabetes – Pipeline by Dance Biopharm Inc, H2 2017 165

Type 2 Diabetes – Pipeline by Delpor Inc, H2 2017 165

Type 2 Diabetes – Pipeline by Diabetology (Products) Ltd, H2 2017 166

Type 2 Diabetes – Pipeline by DiaMedica Therapeutics Inc, H2 2017 166

Type 2 Diabetes – Pipeline by Diamyd Medical AB, H2 2017 167

Type 2 Diabetes – Pipeline by Diasome Pharmaceuticals Inc, H2 2017 167

Type 2 Diabetes – Pipeline by DiscoveryBiomed Inc, H2 2017 168

Type 2 Diabetes – Pipeline by DNJ Pharma Inc, H2 2017 168

Type 2 Diabetes – Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017 169

Type 2 Diabetes – Pipeline by Elcelyx Therapeutics Inc, H2 2017 169

Type 2 Diabetes – Pipeline by Eli Lilly and Co, H2 2017 170

Type 2 Diabetes – Pipeline by Energenesis Biomedical Co Ltd, H2 2017 170

Type 2 Diabetes – Pipeline by Enteris BioPharma Inc, H2 2017 171

Type 2 Diabetes – Pipeline by Enzene Biosciences Ltd, H2 2017 171

Type 2 Diabetes – Pipeline by Enzo Biochem Inc, H2 2017 171

Type 2 Diabetes – Pipeline by Epichem Pty Ltd, H2 2017 172

Type 2 Diabetes – Pipeline by Eternygen GmbH, H2 2017 172

Type 2 Diabetes – Pipeline by Evotec AG, H2 2017 173

Type 2 Diabetes – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 173

Type 2 Diabetes – Pipeline by Genexine Inc, H2 2017 174

Type 2 Diabetes – Pipeline by Genfit SA, H2 2017 174

Type 2 Diabetes – Pipeline by Genmedica Therapeutics SL, H2 2017 175

Type 2 Diabetes – Pipeline by Genovate Biotechnology Co LTD, H2 2017 175

Type 2 Diabetes – Pipeline by Geropharm LLC, H2 2017 176

Type 2 Diabetes – Pipeline by Gilead Sciences Inc, H2 2017 176

Type 2 Diabetes – Pipeline by GlaxoSmithKline Plc, H2 2017 177

Type 2 Diabetes – Pipeline by Glucox Biotech AB, H2 2017 177

Type 2 Diabetes – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 178

Type 2 Diabetes – Pipeline by Heptares Therapeutics Ltd, H2 2017 178

Type 2 Diabetes – Pipeline by HitGen LTD, H2 2017 178

Type 2 Diabetes – Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017 179

Type 2 Diabetes – Pipeline by Immuron Ltd, H2 2017 179

Type 2 Diabetes – Pipeline by Inflazome Ltd, H2 2017 180

Type 2 Diabetes – Pipeline by Innovative Targeting Solutions Inc, H2 2017 180

Type 2 Diabetes – Pipeline by Inspyr Therapeutics Inc, H2 2017 181

Type 2 Diabetes – Pipeline by InStar Technologies AS, H2 2017 181

Type 2 Diabetes – Pipeline by Intarcia Therapeutics Inc, H2 2017 181

Type 2 Diabetes – Pipeline by Intas Pharmaceuticals Ltd, H2 2017 182

Type 2 Diabetes – Pipeline by Integral Molecular Inc, H2 2017 182

Type 2 Diabetes – Pipeline by Intercept Pharmaceuticals Inc, H2 2017 183

Type 2 Diabetes – Pipeline by Intrexon Corp, H2 2017 183

Type 2 Diabetes – Pipeline by Ionis Pharmaceuticals Inc, H2 2017 184

Type 2 Diabetes – Pipeline by Islet Sciences Inc, H2 2017 184

Type 2 Diabetes – Pipeline by Japan Tobacco Inc, H2 2017 185

Type 2 Diabetes – Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017 185

Type 2 Diabetes – Pipeline by JHL Biotech Inc, H2 2017 186

Type 2 Diabetes – Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H2 2017 186

Type 2 Diabetes – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 187

Type 2 Diabetes – Pipeline by Johnson & Johnson, H2 2017 187

Type 2 Diabetes – Pipeline by Kadimastem Ltd, H2 2017 188

Type 2 Diabetes – Pipeline by Kadmon Corp LLC, H2 2017 188

Type 2 Diabetes – Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017 189

Type 2 Diabetes – Pipeline by Kowa Co Ltd, H2 2017 189

Type 2 Diabetes – Pipeline by Lead Discovery Center GmbH, H2 2017 189

Type 2 Diabetes – Pipeline by Leading BioSciences Inc, H2 2017 190

Type 2 Diabetes – Pipeline by Lexicon Pharmaceuticals Inc, H2 2017 190

Type 2 Diabetes – Pipeline by LG Chem Ltd, H2 2017 191

Type 2 Diabetes – Pipeline by Ligand Pharmaceuticals Inc, H2 2017 191

Type 2 Diabetes – Pipeline by LipimetiX Development Inc, H2 2017 192

Type 2 Diabetes – Pipeline by Longevity Biotech Inc, H2 2017 192

Type 2 Diabetes – Pipeline by Luye Pharma Group Ltd, H2 2017 193

Type 2 Diabetes – Pipeline by Magnus Life Ltd, H2 2017 193

Type 2 Diabetes – Pipeline by MannKind Corp, H2 2017 193

Type 2 Diabetes – Pipeline by Medesis Pharma SA, H2 2017 194

Type 2 Diabetes – Pipeline by Medestea Research & Production SpA, H2 2017 194

Type 2 Diabetes – Pipeline by MedImmune LLC, H2 2017 195

Type 2 Diabetes – Pipeline by Medlab Clinical Ltd, H2 2017 195

Type 2 Diabetes – Pipeline by Melior Discovery Inc, H2 2017 195

Type 2 Diabetes – Pipeline by Mellitech SAS, H2 2017 196

Type 2 Diabetes – Pipeline by Merck & Co Inc, H2 2017 196

Type 2 Diabetes – Pipeline by Mesoblast Ltd, H2 2017 197

Type 2 Diabetes – Pipeline by Metabolic Solutions Development Company LLC, H2 2017 197

Type 2 Diabetes – Pipeline by Metabolys SAS, H2 2017 198

Type 2 Diabetes – Pipeline by Metacrine Inc, H2 2017 198

Type 2 Diabetes – Pipeline by Mitsubishi Chemical Holdings Corp, H2 2017 198

Type 2 Diabetes – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 199

Type 2 Diabetes – Pipeline by Naia Ltd, H2 2017 199

Type 2 Diabetes – Pipeline by Neurimmune Holding AG, H2 2017 200

Type 2 Diabetes – Pipeline by Neurocrine Biosciences Inc, H2 2017 200

Type 2 Diabetes – Pipeline by NGM Biopharmaceuticals Inc, H2 2017 201

Type 2 Diabetes – Pipeline by Nordic Bioscience A/S, H2 2017 201

Type 2 Diabetes – Pipeline by Novapeutics LLC, H2 2017 201

Type 2 Diabetes – Pipeline by Novartis AG, H2 2017 202

Type 2 Diabetes – Pipeline by NovaTarg Therapeutics Inc, H2 2017 202

Type 2 Diabetes – Pipeline by Novo Nordisk AS, H2 2017 203

Type 2 Diabetes – Pipeline by Omeros Corp, H2 2017 204

Type 2 Diabetes – Pipeline by OPKO Biologics Ltd, H2 2017 204

Type 2 Diabetes – Pipeline by OPKO Health Inc, H2 2017 205

Type 2 Diabetes – Pipeline by Oramed Pharmaceuticals Inc, H2 2017 205

Type 2 Diabetes – Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2017 206

Type 2 Diabetes – Pipeline by Peptron Inc, H2 2017 206

Type 2 Diabetes – Pipeline by Pfizer Inc, H2 2017 207

Type 2 Diabetes – Pipeline by PharmaCyte Biotech Inc, H2 2017 207

Type 2 Diabetes – Pipeline by PharmaIN Corp, H2 2017 208

Type 2 Diabetes – Pipeline by Pila Pharma AB, H2 2017 208

Type 2 Diabetes – Pipeline by Poxel SA, H2 2017 209

Type 2 Diabetes – Pipeline by Prometheon Pharma LLC, H2 2017 209

Type 2 Diabetes – Pipeline by ProMetic Life Sciences Inc, H2 2017 210

Type 2 Diabetes – Pipeline by Prothena Corp Plc, H2 2017 210

Type 2 Diabetes – Pipeline by Purzer Pharmaceutical Co Ltd, H2 2017 210

Type 2 Diabetes – Pipeline by Reata Pharmaceuticals Inc, H2 2017 211

Type 2 Diabetes – Pipeline by ReCyte Therapeutics Inc, H2 2017 211

Type 2 Diabetes – Pipeline by reMYND NV, H2 2017 212

Type 2 Diabetes – Pipeline by Renova Therapeutics Inc, H2 2017 212

Type 2 Diabetes – Pipeline by Reset Therapeutics Inc, H2 2017 213

Type 2 Diabetes – Pipeline by Saniona AB, H2 2017 213

Type 2 Diabetes – Pipeline by Sanofi, H2 2017 214

Type 2 Diabetes – Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2017 214

Type 2 Diabetes – Pipeline by SATT Conectus Alsace SAS, H2 2017 214

Type 2 Diabetes – Pipeline by SBI Pharmaceuticals Co Ltd, H2 2017 215

Type 2 Diabetes – Pipeline by Seres Therapeutics Inc, H2 2017 215

Type 2 Diabetes – Pipeline by Serodus ASA, H2 2017 216

Type 2 Diabetes – Pipeline by Serometrix LLC, H2 2017 216

Type 2 Diabetes – Pipeline by Sevion Therapeutics Inc, H2 2017 217

Type 2 Diabetes – Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H2 2017 217

Type 2 Diabetes – Pipeline by Shionogi & Co Ltd, H2 2017 217

Type 2 Diabetes – Pipeline by Sirona Biochem Corp, H2 2017 218

Type 2 Diabetes – Pipeline by SJT Molecular Research SL, H2 2017 218

Type 2 Diabetes – Pipeline by SK Chemicals Co Ltd, H2 2017 219

Type 2 Diabetes – Pipeline by Sprint Bioscience AB, H2 2017 219

Type 2 Diabetes – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017 220

Type 2 Diabetes – Pipeline by Suzuken Co Ltd, H2 2017 220

Type 2 Diabetes – Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2017 221

Type 2 Diabetes – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 221

Type 2 Diabetes – Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017 222

Type 2 Diabetes – Pipeline by Teijin Pharma Ltd, H2 2017 222

Type 2 Diabetes – Pipeline by The Medicines Company, H2 2017 223

Type 2 Diabetes – Pipeline by Theracos Inc, H2 2017 223

Type 2 Diabetes – Pipeline by Thermalin Diabetes LLC, H2 2017 224

Type 2 Diabetes – Pipeline by Tiziana Life Sciences Plc, H2 2017 224

Type 2 Diabetes – Pipeline by Toray Industries Inc, H2 2017 225

Type 2 Diabetes – Pipeline by Torrent Pharmaceuticals Ltd, H2 2017 225

Type 2 Diabetes – Pipeline by Transgene Biotek Ltd, H2 2017 226

Type 2 Diabetes – Pipeline by TTY Biopharm Company Ltd, H2 2017 226

Type 2 Diabetes – Pipeline by Twoxar Inc, H2 2017 227

Type 2 Diabetes – Pipeline by Uni-Bio Science Group Ltd, H2 2017 227

Type 2 Diabetes – Pipeline by ViaCyte Inc, H2 2017 227

Type 2 Diabetes – Pipeline by Vichem Chemie Research Ltd, H2 2017 228

Type 2 Diabetes – Pipeline by Vicore Pharma AB, H2 2017 228

Type 2 Diabetes – Pipeline by Viking Therapeutics Inc, H2 2017 229

Type 2 Diabetes – Pipeline by Vivus Inc, H2 2017 229

Type 2 Diabetes – Pipeline by vTv Therapeutics Inc, H2 2017 230

Type 2 Diabetes – Pipeline by Vybion Inc, H2 2017 230

Type 2 Diabetes – Pipeline by XBiotech Inc, H2 2017 230

Type 2 Diabetes – Pipeline by XL-protein GmbH, H2 2017 231

Type 2 Diabetes – Pipeline by XOMA Corp, H2 2017 231

Type 2 Diabetes – Pipeline by XuanZhu Pharma Co Ltd, H2 2017 232

Type 2 Diabetes – Pipeline by Yabao Pharmaceutical Group Co Ltd, H2 2017 232

Type 2 Diabetes – Pipeline by Yuhan Corp, H2 2017 233

Type 2 Diabetes – Pipeline by Yungjin Pharm Co Ltd, H2 2017 233

Type 2 Diabetes – Pipeline by Zafgen Inc, H2 2017 234

Type 2 Diabetes – Pipeline by Zealand Pharma AS, H2 2017 234

Type 2 Diabetes – Dormant Projects, H2 2017 1073

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..1), H2 2017 1074

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..2), H2 2017 1075

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..3), H2 2017 1076

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..4), H2 2017 1077

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..5), H2 2017 1078

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..6), H2 2017 1079

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..7), H2 2017 1080

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..8), H2 2017 1081

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..9), H2 2017 1082

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..10), H2 2017 1083

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..11), H2 2017 1084

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..12), H2 2017 1085

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..13), H2 2017 1086

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..14), H2 2017 1087

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..15), H2 2017 1088

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..16), H2 2017 1089

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..17), H2 2017 1090

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..18), H2 2017 1091

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..19), H2 2017 1092

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..20), H2 2017 1093

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..21), H2 2017 1094

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..22), H2 2017 1095

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..23), H2 2017 1096

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..24), H2 2017 1097

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..25), H2 2017 1099

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..26), H2 2017 1100

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..27), H2 2017 1101

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..28), H2 2017 1102

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..29), H2 2017 1103

Type 2 Diabetes – Dormant Projects, H2 2017 (Contd..30), H2 2017 1104

Type 2 Diabetes – Discontinued Products, H2 2017 1105

Type 2 Diabetes – Discontinued Products, H2 2017 (Contd..1), H2 2017 1106

Type 2 Diabetes – Discontinued Products, H2 2017 (Contd..2), H2 2017 1107

Type 2 Diabetes – Discontinued Products, H2 2017 (Contd..3), H2 2017 1108

Type 2 Diabetes – Discontinued Products, H2 2017 (Contd..4), H2 2017 1109

Type 2 Diabetes – Discontinued Products, H2 2017 (Contd..5), H2 2017 1110

Type 2 Diabetes – Discontinued Products, H2 2017 (Contd..6), H2 2017 1111

Type 2 Diabetes – Discontinued Products, H2 2017 (Contd..7), H2 2017 1112

Type 2 Diabetes – Discontinued Products, H2 2017 (Contd..8), H2 2017 1113

Type 2 Diabetes – Discontinued Products, H2 2017 (Contd..9), H2 2017 1114

List of Figures

List of Figures

Number of Products under Development for Type 2 Diabetes, H2 2017 67

Number of Products under Development by Companies, H2 2017 68

Number of Products under Development by Universities/Institutes, H2 2017 84

Number of Products by Top 10 Targets, H2 2017 121

Number of Products by Stage and Top 10 Targets, H2 2017 121

Number of Products by Top 10 Mechanism of Actions, H2 2017 130

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 130

Number of Products by Top 10 Routes of Administration, H2 2017 139

Number of Products by Stage and Top 10 Routes of Administration, H2 2017 139

Number of Products by Top 10 Molecule Types, H2 2017 141

Number of Products by Stage and Top 10 Molecule Types, H2 2017 141

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports